1. Survival impact of early lymph node staging in a national study on 454 Danish men with penile cancer
- Author
-
Jakobsen, J. K., Krarup, K. P., Sommer, P., Nerstrom, H., Sørensen, Jens Ahm, Bakholdt, V., Olsen, K. Ø., Kromann, B., and Jensen, J. B.
- Subjects
survival *lymph node *staging *male *human *penis cancer *European *urology patient neoplasm cancer staging proportional hazards model hazard ratio Kaplan Meier method diagnosis cancer specific survival follow up Charlson Comorbidity Index cancer patient population model confidence interval metastasis cancer control physician prognosis university hospital cancer diagnosis comorbidity patient coding squamous cell carcinoma - Abstract
INTRODUCTION & OBJECTIVES: In few other cancers lymph node involvement has as clear a prognostic significance as in penile cancer. The latest revision of the Union for International Cancer Control Tumour Node Metastasis (TNM) - criteria for penile cancer in 2009 amended the pathological nodal (pN) stage so extranodal metastatic extension entails stage pN3. We report population based national survival data from 454 Danish penile cancer patients staged according to the TNM 2009 criteria and evaluate the survival impact of lymph node staging at diagnosis. MATERIAL & METHODS: Penile squamous cell carcinoma patient data from five university hospitals from the period 2000 - 2010 was retrospectively collected by one medical doctor. Vital status was defined in October 2014. Survival was assessed by the means of the Kaplan-Meier method and hazard ratios estimated by Cox regression with 95% confidence intervals. Survival impact of lymph node staging was evaluated in a multivariate cox regression model with adjustment for tumour stage, age and Charlson comorbidity score. RESULTS: Of a total of 454 men 39 did not undergo lymph node staging of any kind. Median follow-up of patients who survived was 7.5 years (interquartile range: 5.6-10.5 years). Figure 1 shows the Kaplan-Meier curves for all-cause and penile cancer specific survival related to lymph node stage. All cause 5-year survival for pN0, pN1, pN2, pN3 and pNx patients was 84 (79-87) %, 60 (42-75) %, 54 (33-71) %, 12 (5-22) and 31 (17-45) %. Penile cancer-specific 5-year survival for pN0, pN1, pN2, pN3 and pNx patients was 97 (94-98)%, 82 (62- 92)%, 57 (36-74)%, 12 (5-22)% and 53 (35-69)%. Lymph node staging had a significant impact on penile cancer specific survival after adjustment for age, T-stage and comorbidity (Nx vs all N0, N1, N2, N3 patients) with a hazard ratio of 3.5 (95% CI 2.0 to 6.0). CONCLUSIONS: In this national study, we found both cancer specific and all-cause survival significantly correlated to TNM-2009 lymph node stage at penile cancer diagnosis. Delayed lymph node staging (Nx) was significantly correlated to poorer prognosis underlining the importance of performing lymph node staging at diagnosis.
- Published
- 2015
- Full Text
- View/download PDF